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NOVELTY STATEMENT:
1. What is the NEW aspect of your work? To the best of our knowledge, here we present the 
first manuscript to report efficacy and safety clinical practice data of eltrombopag in elderly ITP 
patients.
2. What is the CENTRAL finding of your work? Efficacy and safety of eltrombopag in daily 
practice is high even in patients 65 years old or older with immune thrombocytopenia.
3. What is (or could be) the SPECIFIC clinical relevance of your work? Our paper shows 
eltrombopag has great effectiveness and a good safety profile in special populations such as 
elderly ITP patients.
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ABSTRACT
Background: Eltrombopag is useful for immune thrombocytopenia (ITP). However, results of 
clinical trials may not accurately mirror clinical practice reality. Here we evaluated eltrombopag 
for primary and secondary ITP in our ≥65-yr-old population. Methods: 106 primary ITP patients 
(16 with newly-diagnosed ITP, 16 with persistent ITP and 74 with chronic ITP) and 39 secondary 
ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious 
diseases and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively 
evaluated. Results: Median age of our cohort was 76 (interquartile range, IQR, 70-81) years. 
75.9% of patients yielded a platelet response including 66.2% complete responders. Median time 
to platelet response was 14 (IQR, 8-21) days. Median time on response was 320 (IQR, 147-526) 
days. 63 adverse events (AEs), mainly grade 1–2, occurred. The most common were hepatobiliary 
laboratory abnormalities (HBLAs) and headaches. One transient ischemic attack in a newly 
diagnosed ITP and two self-limited pulmonary embolisms in secondary ITP were the only 
thrombotic events observed. Conclusion: Eltrombopag showed efficacy and safety in ITP patients 
aged ≥65 years with primary and secondary ITP. However, efficacy results in LPD-ITP were poor. 
A relatively high number of deaths were observed.
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Introduction
Immune thrombocytopenia (ITP) is an acquired antibody-mediated immune disorder characterized 
by increased destruction and inadequate platelet production (1). Incidence of ITP increases with 
age (2) with no difference for sexes in over 60 year-old patients (3). ITP is clinically variable 
among patients (4) with those aged ≥60 years at enhanced risk for both major non-fatal and fatal 
hemorrhage (5). 
ITP remains to be an exclusion diagnosis. Thus, primary ITP is defined as a platelet count < 100 x 
109/L when other possible causes of thrombocytopenia are discarded (6, 7). On the other hand, 
secondary ITP represents close to 20% of ITP in adults (8) and is often due to other conditions 
such as immune, infectious or neoplastic disorders (9). 
Primary ITP treatment tries to ameliorate hemorrhages and avoid new episodes if possible (7, 10). 
Standard first-line primary ITP treatment continues to be steroids. Intravenous immunoglobulins 
are usually reserved to treat bleeding cases. In refractory-to-first-line-treatment patients or 
relapsing situations, splenectomy is the traditional second line option. Although other therapies 
have relegated surgery use, splenectomy is still considered the only ITP curative treatment with 
the highest long-response rates reported to date (11, 12). Conversely, secondary ITP is often 
refractory to steroids and splenectomy (13) being the outcome of underlying disease usually 
parallel with improvement of thrombocytopenia (14).
Eltrombopag is an oral thrombopoietin receptor agonist drug (TPO-RA) which induces 
proliferation and differentiation of megakaryocytes and stimulates platelet production via 
JAK/STAT signaling pathway (15). Results of clinical trials show great efficacy of eltrombopag 
(around 80%) in achieving hemostatic platelet levels (≥50 x 109/L) with good tolerance (less than 
5% of grade 3-4 side effects). This efficacy and safety data is reported to be very prolonged in 
time with a follow-up of up to 9 years (16). Although elderly and super-elderly patients were 
enrolled in clinical trials, (e.g. maximum age of 86 years in EXTEND trial), these studies may not 
reflect reality in over 65-yr-old ITP patients. Nevertheless, in last years good few studies regarding 
eltrombopag use in primary ITP beyond clinical trials were published (17-19) and increasing 
number of papers is available for elderly situations (20-27). Regarding secondary ITP, lack of 
clinical trials and shortage of publications outside of clinical trials avoid a clear demonstration of 
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The aim of our present study is to evaluate safety and efficacy of eltrombopag for primary and 
secondary ITP in patients aged ≥ 65 years in Spanish routine clinical practice.
Material and Methods
Patients and study design
Here we retrospectively evaluated 106 primary and 39 secondary ITP patients (aged 65 years or 
more) from 20 Spanish centers who had been treated with eltrombopag. Researchers reviewed 
clinical charts and collected biological and clinical patient data by means of a predetermined case 
report form. There were recorded patient and disease characteristics including age, gender, months 
since diagnosis, prior-to-eltrombopag ITP treatments, underlying disease treatments (in secondary 
ITP only), platelet levels (at diagnosis and before and during eltrombopag treatment), duration and 
dose of eltrombopag treatment, and adverse events (AEs) during treatment.
Eltrombopag for primary ITP was administered at standard doses approved by  European 
Medicines Agency. The same standard doses (25-75mg/day) were used for secondary ITP when 
standard ITP treatment failed.
Primary ITP was defined as a platelet count of <100 x 109/L in the absence of other causes or 
diseases that might be associated with thrombocytopenia. The terms “newly diagnosed ITP, 
persistent and chronic ITP” were reserved for patients whose condition had lasted for less than 3 
months, 3-12 months and more than 12 months respectively (6). The term “secondary ITP” 
included all forms of immune-mediated thrombocytopenia with a platelet count of <100 x 109/L 
except primary ITP. Given that the diagnosis of primary ITP remains one of exclusion with no 
robust clinical or laboratory parameters available, many authors suggest that no response to 
platelet transfusion and, on the contrary, rapid response (<1 week) to high dose immunoglobulins 
(IVIg) could be a necessary condition so as to diagnose ITP (either primary or secondary). So, our 
patients had to comply with this requirement to be adequate for enrollment. Obviously, other 
factors involved in non-immune thrombocytopenia had also to be discarded. 
We studied in our work immune thrombocytopenia secondary to autoimmune diseases, 
lymphoproliferative disorders and viral infections (i.e. HCV, HIV). For the diagnosis of these 
three different subtypes of secondary ITP, we used two additional definitions. Thus, diagnosis of 
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109 platelets/L and half the initial platelet count without alterations in peripheral blood smear, in 
presence of an already stablished viral infection or autoimmune disorder related to an immune 
thrombocytopenia with no other possible explanation by means of medical conditions or 
treatments. Our diagnostic criteria also included the definition of ITP secondary to 
lymphoproliferative disorders (30), i.e. acute and severe thrombocytopenia (less than 2 weeks of 
duration), absence of splenomegaly, infection or cytotoxic treatments during last month with 
normal or augmented number of bone marrow megakaryocytes. Although there was no standard 
panel of testing to discard possible causes of secondary ITP, all physicians were advised to follow 
McMaster ITP diagnosis criteria (31).
Physician staff evaluated comorbidities at ITP diagnosis and soon afterwards classified them 
according with the age-adjusted Charlson Comorbidity Index (CCI). To point out, CCI is a list of 
19 comorbid terms, each of them with a value ranking from 1 to 6 that predicts the ten-year 
mortality of our patients. 
First we evaluated efficacy of eltrombopag. Thus, we followed international criteria to define 
complete response (CR) as a platelet count of ≥100 x 109/L and absence of hemorrhages. 
Response (R) was defined as a platelet count of 30–100 x 109/L, at least a twofold increase of the 
platelet baseline count with resolution of bleeding symptoms. No response (NR) was defined as a 
platelet count of < 30 x 109/L or less than twice the platelet baseline count (6). Response definition 
also needed a concurrent absence of any rescue intervention during 8 weeks previous to 
eltrombopag treatment.
Duration of eltrombopag response (or complete response) was measured as the proportion of 
cumulative time spent in R (or CR) during the period of examination (6). ITP treatment failure 
was defined as a platelet count of < 30 x 109/L for 4 consecutive weeks at the highest standard 
dose approved by European Medicines Agency in primary ITP or at 75 mg per day in secondary 
ITP, a major bleeding event, or the need to change therapy (including splenectomy and/or any 
other rescue treatment). Higher dose than baseline of a concomitant treatment to eltrombopag was 
considered as a rescue treatment. We evaluated and classified adverse events during eltrombopag 
treatment according to the National Cancer Institute Common Terminology Criteria for Adverse 
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Our study was performed in accordance with the guidelines of institutional boards of the 20 
participating centers and the standards of the Helsinki Declaration. It was approved by Hospital 
Universitario de Burgos Ethics Committee (protocol code – REVOES-SCL-ET-2014-01) and was 
authorized afterwards as a post-authorization observational study by the Spanish Medicines and 
Health Products Agency. Informed consent of the patients was obtained prior to enrollment. 
Actual position of the protocol involves only spanish eltrombopag ITP treated patients.
Statistical analysis
A descriptive statistical analysis was performed in Excel (Microsoft Corp., Redmond, WA). 
Normally and non-normally distributed continuous variables were respectively summarized as the 
mean and standard deviation (SD), and as the median and interquartile range (IQR). Discrete 
variables were summarized as percentages. Quantitative and qualitative data were compared using 
the Mann–Whitney U and Fisher’s exact tests, respectively. When analyzing three or more groups, 
Kruskal-Wallis test was used instead of Mann–Whitney U test. Statistical significance was 
concluded for values of p < 0.05. All statistical analyses were performed using SPSS version 19.0 
for Windows (SPSS, Chicago, IL, USA).
Results
Patient characteristics
106 primary ITP and 39 secondary ITP patients aged ≥ 65 years who received eltrombopag 
treatment were recruited from 20 Spanish centers for this study. According to standard definition, 
we allocated our primary ITP cohort to three groups: 16 newly-diagnosed ITP, 16 persistent ITP 
and 74 chronic ITP patients. Meanwhile, in the secondary ITP cohort we collected 20 patients with 
ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases (HCV and/or 
HIV) and 12 with ITP secondary to neoplastic (lymphoproliferative disorder-LPD) conditions. 
Underlying diseases causing secondary ITP were: chronic lymphocytic leukaemia (CLL) in 6 
cases, 6 cases of hepatitis C virus (HCV),  5 patients with Sjögren syndrome, 4 anti-phospholipid 
(aPL) syndromes, 4 Waldenstrom macroglobulinemia (WM), systemic lupus erythematosus (SLE) 
in 3 cases, 3  cases of Evans syndrome, 2  rheumatoid arthritis, 2 patients with  other lymphoma 
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specified [PTCL-NOS]), 1 patient with primary biliary cirrhosis, 1 Graves-Basedow patient 
(autoimmune thyroid disease), 1 antiphospholipid syndrome-SLE patient and 1 case with Evans 
Syndrome-HCV. 
The main demographic and hematological features of our elderly population cohort are presented 
in Table 1. Median age of the whole cohort was 76 years [interquartile range (IQR), 70–81 years] 
with a majority of female patients (65%). 23% of patients had a Charlson comorbidity index 
greater than one at diagnosis. Months with ITP at the time eltrombopag was started were 30 
months (IQR, 4–101 months). Median prior ITP treatments before eltrombopag was 2 (IQR, 2–4). 
Of these, 17% patients had previously received romiplostim and 22% rituximab. To note, only 
17% of patients were splenectomized. Finally, median platelet count at eltrombopag initiation was 
14 x 109 /l (IQR, 8–28 109/l). 
Furthermore, we also observed primary and secondary elderly ITP cohorts characteristics. Here, 
both ITP diseases were homogeneous concerning most important parameters. Thus, median age of 
primary and secondary ITP cohorts was similar: 76 (IQR, 71–81) vs 74 (IQR, 68–78) years, 
respectively. Both thrombocytopenic conditions affected predominantly women (68, 64% in 
primary ITP vs 26, 66.6% in secondary ITP) with identical median number of therapies previous 
to eltrombopag initiation (2, IQR, 2–4) and low rates of prior splenectomy (17% vs 18%). 
However, significant statistical differences were found between both cohorts regarding Charlson 
comorbidity Index (24% of primary ITP had an index greater than one vs 19% in secondary ITP, 
p=0.004), ITP duration since diagnosis (35 [7;122] vs 15[2;55] months, p=0.021) and concomitant 
treatments (32, 30.2% vs 28, 69.2% patients receiving another ITP treatment simultaneously, 
p=0.000). To note, bleeding during the month before starting eltrombopag nearly reached 
statistical significance (31, 29% vs 16, 47%, p=0.056). Table 2 separately describes patient 
characteristics of the three subgroups of primary ITP. Nevertheless, no statistical differences were 
observed regarding clinical and epidemiological data of all three secondary ITP subtypes. 
With the aim to look for differences regarding patient characteristics and following the scheme  of 
previous publications (26,27), we divided our whole patient populations in two different cohorts: 
65-74 year-old and 75-and-above year old ITP patients. Unfortunately, no statistical differences 
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110 of 145 ITP patients (75.9%) of our whole elderly cohort yielded a platelet response (R) while 
96 (66.2%) reached a complete response (CR). Subgroup analysis showed 83 (82%) primary ITP 
and 23 (59%) secondary ITP responders. This difference was statistically significant . Quite 
similar results were 80 (75%) primary ITP and 16 (41%) secondary ITP patients who achieved a 
CR. To note, platelet responses of whole, primary and secondary ITP cohorts are described in 
Table 4. Furthermore responses and complete responses were comparable in all primary ITP 
groups. On the contrary, secondary ITP efficacy results show high response rates achieved in 
immune (12, 60%) and infectious cohorts (6, 86%) but poor results in neoplastic cohort (5, 42%).
Response rate of whole cohort at 3 months was 66.9% with a CR rate of 49.6%. Statistically 
significant differences (p value = 0.043) where found when we compared responses in both 
primary (76, 72%) and secondary ITP (21, 54%). On the other hand, CR rates in primary ITP (62, 
58%) were much higher than results obtained in secondary ITP patients (10, 26%). This CR rate 
difference was maintained at 6 months. Nevertheless, no significant differences in durable 
responses of the groups were observed (Figure 1). Median time to platelet response was 14 days 
(14 in primary ITP and 12 in secondary ITP). Similar results were also obtained in primary and 
secondary ITP subgroups. This term, nevertheless, was significantly longer in neoplastic cohort 
(27 days). Relapse rate was 24.8% (36 of 110 responders) being higher in secondary ITP (14, 
35.9%) than observed in primary ITP (22, 20.7%). During the 15-month follow-up of our study, 
26 patients (17.9%) needed rescue treatments. Interestingly, when compared with 65-74 year-old 
patients, the need for rescue therapy in patients aged ≥ 75 years was higher (20, 76.9%), with 
statistical differences observed between groups. However, all other efficacy data was similar in 
both cohorts. Median time to relapse was 5 months (IQR, 3-9 months). 
Figure 2 and table 5 present response and complete response rates of elderly (65-74 year-old) and 
very elderly (75-and-above year-old) ITP populations. 
Eltrombopag safety
Adverse events and number of deaths during eltrombopag treatment of 65-74 year-old  and 75-
and-above year-old ITP cohorts are presented in Table 6 and 7 respectively. Thus, 48 patients of 
our 145 elderly cohort experienced one or more AEs during eltrombopag treatment. Majority of 
AEs were grade 1-2 in severity. 40 affected primary ITP and 23 secondary ITP patients. The most 
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patients respectively. Nevertheless, 24 AE were serious (grade 3-4). 3 SAEs occurred in newly 
diagnosed ITP: 1 brain haemorrhage in a non-responding ITP, 1 pneumonia in a chronic 
obstructive pulmonary disease patient and 1 transient ischemic attack. The first two patients died. 
The latter two were ITP in CR. Other two grade 3-4 events occurred in persistent ITP, both 
survived: one brain bleeding and one severe asthenia episode which forced eltrombopag 
discontinuation. Chronic ITP cohort registered 10 grade 3-4 AEs, 6 of them died. These deaths 
were 2 brain haemorrhages, 1 gastrointestinal bleeding, 2 sepsis of respiratory origin and 1 
splenectomy septic complications. Other 4 SAEs were an episode of severe diarrhea and 3 cases of 
grade III HBLA that resolved despite continued treatment. In secondary ITP cohort, 9 SAEs were 
recorded: 5, 1 and 3 in immune, infectious and neoplastic (LPD) cohorts, respectively. 6 deaths 
occurred in this cohort: 1 brain haemorrhage in a patient with Evans syndrome in NR, 1 lupus 
patient who developed an acute myeloid leukemia, one multirefractory JAK2 positive 
myelofibrosis in an HCV patient, 1 brain bleeding with a platelet count of 53 x 109/L at the time of 
the event in a CLL patient, 1 episode of febrile neutropenia in a pancytopenic CLL patient and, 
finally, 1 episode of sepsis of unknown origin in a previously responder WM-ITP. The other 3 
SAEs were an HBLA episode who required treatment discontinuation in a Sjögren-ITP, another 
Sjögren related ITP experienced a mild increase of bone marrow reticulin (grade II) but after 
eltrombopag cessation fibrosis decreased to grade I and, finally, a disseminated intravascular 
coagulation (DIC) episode in a non-responder pancytopenic CLL-ITP.  2 patients, 1 APS and 1 
CLL, both with cardiovascular risk factors, experienced both grade 2 episodes of venous 
thromboembolism 12 and 8 months after starting eltrombopag  with platelet counts of 263 and 158 
x109/L respectively, which resolved with medical intervention.
Number of AEs was quite similar in elderly and very elderly populations (30 and 33 respectively). 
8 HBLAs and 4 arthralgias in 65-74 yr-old ITP with 4 diarrheas and 4 upper respiratory tract 
infections in 75-and-above yr-old ITP were the most common adverse events observed. SAEs and 
deaths were higher in very elderly ITP (14, 18.7% and 9,12% respectively). Infections and 
hemorrhages were the most frequent causes of death of the whole cohort. Despite its low 
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Pivotal trials demonstrate an excellent efficacy and safety profile of eltrombopag in primary ITP 
(16, 32). Besides, our real-life studies have also shown this drug is useful for this type of patients 
(18, 19). On the other hand, the role of eltrombopag in secondary ITP needs to be elucidated. Our 
group was the first to publish a large clinical practice study of 87 secondary ITP patients treated 
with eltrombopag. We reported great evidence in favor of eltrombopag use in ITP secondary to 
both infectious and immune diseases (29). Nevertheless we consider additional trials in this 
context are mandatory. Something similar happens with ITP and aged patients. A classic analysis 
focused on eltrombopag usefulness in elderly patients (i.e. results from 5 eltrombopag clinical 
trials) as reported in abstract form by Olney et al in 2011 (33). Nevertheless, recently a very 
interesting manuscript has been published reporting treatment decision strategies  in the elderly 
ITP. Authors studied TPO-RA use in patients aged >75 years versus <65 years showing a higher 
use of TPO-RAs in the elderly, probably because of comparable response rates of these drugs in 
older and younger patients (26). However, no clear data is achieved about eltrombopag 
effectiveness in daily clinical practice in ITP patients aged ≥65 years. This Spanish elderly ITP 
population study is, to the best of our knowledge, the biggest clinical practice investigation of 
eltrombopag treatment for primary and secondary ITP in 65 years old or older patients.
Here we describe safety and efficacy results of eltrombopag in a cohort of 145 patients 65 years 
old or older. 106 of them were treated for primary ITP and 39 for secondary ITP during a follow-
up of 15 months. Efficacy results in our whole cohort report 75.9% of responders. As expected, 
this efficacy outcome was higher in primary ITP (82%) than in secondary ITP setting (59%). 
Median age of our whole, primary and secondary ITP cohorts was high and quite similar among 
groups. Actually, median age of our primary ITP cohort (76 years) is older than median 
enrollment age of primary ITP clinical trials (e.g. median age of EXTEND trial is 50 years). Given 
that EXTEND clinical trial obtained 91% of responses, we can conclude that regardless of a higher 
age, efficacy results of our primary ITP elderly population are consistent with results of clinical 
trials. We previously reported high response rates in primary ITP regardless of the phase of 
disease studied (18, 19). Outcome results obtained here were akin when we focused on our elderly 
population with 94%, 75% and 81% of responses in newly diagnosed, persistent and chronic ITP 
respectively. Comparable outcome is observed when romiplostim, another TPO agonist, is 
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older primary ITP patients with even slightly greater platelet responses in the population aged ≥65 
years (23). 
In our case series, 4 primary ITP patients suffered from serious brain hemorrhages. All of them 
were shown to be refractory to eltrombopag. 2 patients were very elderly patients (aged >75 
years). 3 patients (one newly diagnosed and two chronic ITP) died, all of them with a platelet 
count lower than 30 x 109/L when bleeding occurred. This finding agrees with the correlation 
between severe bleeding and a very low platelet count observed in previous studies (21). 
Similarly, romiplostim has also demonstrated a low risk of grade ≥3 bleeding in adults aged ≥65 
years (23). Given that elderly patients with low platelet counts have an increased risk of bleeding 
(8, 22, 25, 26), great efficacy and low bleeding rates of eltrombopag in our elderly ITP cohort 
confirm usefulness of the drug, as previously reported by other groups (27).
Frequency of ITP is close to 30% in some diseases (e.g. lymphoid tumors or SLE) (34). However, 
few publications have been issued to date regarding usefulness of TPO analogs in secondary ITP 
of the elderly (17). Thus, limited communications point out their success when treating ITP 
secondary to autoimmune diseases (35) or lymphoproliferative disorders (LPDs) (36) in patients 
aged ≥65 years. Our efficacy results in secondary ITP show high response rates in immune and 
infectious ITP with poor results in LPD-ITP. So, quite similar results to those previously reported 
by our group (29). 6 deaths occurred in this cohort but only 2 were directly related to treatment 
failure (2 brain haemorrhages in an Evans syndrome and in a CLL patient respectively, both very 
elderly patients). Therefore, here we demonstrate eltrombopag can also be effective in secondary 
ITP in elderly situations. This conclusion gets special relevance if we consider secondary ITP is 
often multirefractory to treatments (37). 
48 patients of our whole cohort suffered from AEs during treatment. Similar rates of SAEs (grade 
3-4 adverse events) were reported both in primary (15, 37.5%) and secondary (9, 39.1%) ITP 
groups but 14 (58.3%) of them were observed in very elderly ITP. If we focus on our chronic ITP 
group we observe 10 (32.2%) SAEs. To note, in EXTEND trial 97 patients (32%) experienced 
SAEs being headache (86, 28%) and nasopharyngitis (74, 25%) the most frequent (16). By 
contrast, previous communications communicated fatigue, constipation and cataracts as the more 
frequent AEs in older patients (33). Here we found 63 AEs (40 in primary ITP cohort and 23 in 
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Nevertheless, given that it is expected to yield a twofold increase of treatment-related adverse 
event rate in elderly ITP (21), our study reflects consistent results with prior publications and an 
acceptable safety profile of eltrombopag, especially if we take into account the high comorbidity 
rate of any elderly ITP population. Even more when we report here a similar rate of AEs 
regardless of elderly or very elderly condition.
Thrombotic risk in immune thrombocytopenia is controversial. Some authors find a trend towards 
elevated thromboembolic rates in ITP (38) specially in patients with  comorbidities (39), while 
others do not (40). Thus, Italian group reports higher thrombosis incidence in the elderly (26). 
Furthermore, some studies suggest TPO-RA use predisposes to thrombosis (22), while other 
publications do not find that association (40) even in elderly populations (27). Recently, Wong et 
al (2017)  reported EXTEND study results with 19 chronic primary ITP patients (6%) who 
experienced thrombotic events (16). Likewise, one transient ischemic attack in a CR newly 
diagnosed ITP is the only thrombotic event we observed in our primary ITP cohort. Michel et al 
(2011) yielded similar results, only 2 suspected pulmonary embolisms, when analyzing their 
single-center experience with 55 patients aged ≥70 years (21). Unlike this, Olney et al, 2011 
reported an elevated incidence of thromboembolic events (9%) in patients ≥65 years treated with 
eltrombopag (33). Risk of venous thrombosis is high in many autoimmune disorders (41). 
However, low evidence exists about thromboembolic risk in secondary ITP and TPO-RA. In our 
case series, only 2 secondary ITP patients (one APS male and one CLL-ITP female) experienced a 
self-limited pulmonary embolism as a side effect of eltrombopag. In fact, risk of thrombosis when 
receiving TPO analogs still remains on discussion, especially in older patients with high risk for 
thromboembolic events (32). Our study supports a low thrombotic risk for eltrombopag in elderly 
ITP.
We noticed that more severe side effects usually affected to our very elderly adult patients. 
Moreover, majority of deaths of our whole ITP cohort were in aged >75 years ITP. 8 deaths 
occurred in primary ITP and 6 in secondary ITP. Probably, number of deaths of our case series is 
relatively high. However, given the elevated age of our population and its high number of 
comorbidities, we consider safety profile of eltrombopag in this scenario is good and comparable 
to our previous observations with younger cohorts (18,19,29). Similarly, prior publications 
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The possibility of major selection bias and the retrospective data analysis are the principal 
limitations of our study. Despite these restrictions, our study demonstrates efficacy and good 
tolerance of eltrombopag in elderly setting.
In summary, in our daily clinical practice, eltrombopag is effective and safe in unselected patients 
65 years old or older with primary ITP. However,  efficacy results  of eltrombopag in secondary 
ITP are quite good for immune and infectious secondary ITP cohorts, but unfortunately its 
efficacy is low for the neoplastic cohort.  On the other hand, many safety corcerns with our 
secondary ITP population were observed in the neoplastic cohort of the study.
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Table 1. Patient characteristics: whole, primary and secondary ITP cohorts 
 
Table 1. Patient characteristics Whole cohort Primary ITP Secondary ITP p value 
Variable Total 
(n = 145) 
Total 
(n = 106) 
Total 
(n = 39) 
 
Age, years, median [Q1;Q3] 76 [70;81] 76 [71;81]  74 [68;78]  0.090 
Women (n) 51/94 38 / 68  13/26   0.778 
Charlson comorbidity Index > 1, % 23 24 19 0.004 
Months with ITP, median [Q1;Q3]  30 [4;101] 35 [7;122] 15 [2;55] 0.021 
Past ITP treatments, median [Q1;Q3] 2 [2;4] 2 [2;4] 2 [2;4] 0.354 
    Splenectomy, n (%) 25 (17) 18 (17) 7 (18) 0.986 
    Rituximab, n (%) 32 (22) 20 (19) 12 (31) 0.166 
    Romiplostim, n (%) 25 (17) 19 (18) 6 (15) 0.635 
Platelet count at start of eltrombopag treatment (x109/L), median [Q1;Q3] 14 [8;28] 14 [8;28] 14 [7;28] 0.451 
Bleeding at start of eltrombopag treatment, n (%) 47 (32) 31 (29) 16(47) 0.056 
Concomitant treatment, n (%) 60 (41.4)  32 (30.2) 28 (69.2) 0.000 
   Corticoids 34 (23.4)  16 (15.1) 18 (46.1) 0.949 
   Immunoglobulins 10 (6.9)   7 ( 6.7)  3 (7.7) 0.169 
   Corticoids plus immunoglobulins 10 (6.9)   6 (5.7)  4 (10.2) 0.336 
   Chemotherapy 4 (2.75)   1 (1)  3 (5.1) 0.336 









   Splenic radiotherapy 1 (0.6)   1 (1)  0 (0) 1.000 
 
Table 2. Patient characteristics of primary ITP cohorts: newly diagnosed ITP (A), persistent ITP (B) and chronic ITP (C) 
 
Table 2. Patient characteristics Newly diagnosed ITP Persistent ITP Chronic ITP p value 
Variable Total 
(n = 16) 
Total 
(n = 16) 
Total 
(n = 74) 
 
Age, years, median [Q1;Q3] 79 [71;81]  76 [73;85]  76 [71;81]  0,280 
Women (n) 6/10  9/7  23/51  0,162 
Charlson comorbidity Index > 1, % 43 19 22 0,324 
Months with ITP, median [Q1;Q3]  1 [0;2] 5 [4;9] 70 [31;184] 0.000 
Past ITP treatments, median [Q1;Q3] 2 [1;3] 2 [1;2] 3 [2;4] 0.000 
    Splenectomy, n (%) 1 (6) 0 (0) 17 (23) 0.652 
    Rituximab, n (%) 2 (12) 1 (6) 17 (23) 0.329 
    Romiplostim, n (%) 2 (12) 2 (12) 15 (20) 0.415 
Platelet count at start of eltrombopag treatment (x109/L), median [Q1;Q3] 11 [6;32] 14 [4;20] 16 [8;32] 0.447 
Bleeding at start of eltrombopag treatment, n (%) 6 (38) 8 (50) 17 (23) 0.358 
Concomitant treatment, n (%) 5 (31.2) 6 (37.5)  21 (28.4) 0.185 
   Corticoids 2 (12.5) 5 (31.2)  9 (12.2) 0.220 
   Immunoglobulins 0 (0) 0 (0)  7 (9.4) 0.350 
   Corticoids plus immunoglobulins 1 (6.25) 1 (6.2)  4 (5.4) 0.159 
   Rituximab 0 (0) 0 (0)  1 (1.3) 0.305 









   Splenic radiotherapy 1 (6.25) 0 (0)  0 (0) 0.847 
 
 
Table 3. Patient characteristics: 65-74 yr-old and ≥75 yr-old ITP cohorts 






Age, years, median [Q1;Q3] 70 [67;73]  81 [78;84]  0.000 
Women (n) 29/41  22/53   0.127 
Charlson comorbidity Index > 1, % 23 24 0.431 
Months with ITP, median [Q1;Q3]  40 [6;108] 21 [4;66] 0.108 
Past ITP treatments, median [Q1;Q3] 2 [2;4] 3 [2;4] 0.976 
    Splenectomy, n (%) 16 (22.8) 9 (12.0) 0.089 
    Rituximab, n (%) 18 (25.7) 14 (18.7) 0.322 
    Romiplostim, n (%) 12 (17.1) 13 (17.3) 0.950 
Platelet count at start of eltrombopag treatment (x109/L), median [Q1;Q3] 17 [9;30] 13 [7;24] 0.095 
Bleeding at start of eltrombopag treatment, n (%) 19 (27.1) 28 (37.3) 0.258 
Concomitant treatment, n (%)  23 (32.8) 34 (45.3) 0.141 
   Corticoids  15 (21.4) 19 (25.3) 0.481 
   Immunoglobulins   3 ( 4.3)  7 (9.3) 0.724 
   Corticoids plus immunoglobulins   4 (5.7)  6 (8.0) 1.000 









                                  
   Rituximab   1 (1.4)  0 (0) 0.404 
   Splenic radiotherapy   0 (0)  1 (1.3) 1.000 
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Table 4. Platelet response: whole, primary and secondary ITP cohorts  
Table 4.  Platelet Response Whole cohort Primary ITP Secondary ITP p value  
Variable Total 
(n = 145) 
Total 
(n = 106) 
Total 
(n = 39) 
  




Patients with a platelet response (R), n (%) 110 (75.9) 87 (82)  23 (59)  0.004  
Patients with a complete platelet response (CR), n (%) 96 (66.2) 80 (75) 16 (41) 0.052  
Number of days to platelet response, median [Q1;Q3] 14 [8;21] 14 [8-21] 12 [9-13] 0.741  
Number of days to complete platelet response, median [Q1;Q3] 20 [12;47] 17 [11-45] 25 [14-58] 0.083  
Duration of response      
Months with eltrombopag, median [Q1;Q3] 11 [5-18] 12 [5-19] 9 [3-18] 0.648  
Platelet response (R) at 3 months, n (%) 97 (66.9) 76 (72) 21 (54) 0.043  
Platelet complete response (CR) at 3 months, n (%) 72 (49.6) 62 (58) 10 (26) 0.000  
Platelet response (R) at 6 months, n (%) 83 (57.2) 65 (61) 18 (46) 0.102  
Platelet complete response (CR) at 6 months, n (%) 57 (39.3) 53 (50) 4 (10.2) 0.074  
Days on response, median [Q1;Q3] 320 [147;526] 334 [165;529] 227 [111;648] 0.786  
Days on platelet complete response (CR), median [Q1;Q3] 213 [84;398] 247 [104;413] 139 [75;297] 0.197  
Treatment failure or relapse      
Rescue treatment, n (%) 26 (17.9) 21 (20) 5 (13) 0.331  
Number of patients with treatment failure or relapse 36 (24.8) 22 (20.7) 14 (35.9) 0.205  
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Immunoglobulins 16 (11.0) 14 (13.2) 2 (5.1) 0.159  
Steroids 4 (2.7) 4 (3.8) 0 (0) 0.252  
Romiplostim 1 (0.7) 1 (0.94) 0 (0) 0.353  
Rituximab 3 (2.1) 1 (0.94) 2 (5.1) 0.684  
Chemotherapy 1 (0.7) 1 (0.94) 0 (0) 0.735  
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Table 5. Platelet response: 65-74 yr-old and ≥75 yr-old ITP cohorts 
                                  
Table 5.  Platelet Response 65-74 yr-old ITP ≥75 yr-old ITP p value 
Variable Total 
(n = 70) 
Total 
(n = 75) 
  




Patients with a platelet response (R), n (%) 52 (74.3)  58 (77.3)  0.668  
Patients with a complete platelet response (CR), n (%) 51 (72.9) 52 (69.3) 0.640  
Number of days to platelet response, median [Q1;Q3] 14 [8-21] 14 [9-21] 0.928  
Number of days to complete platelet response, median [Q1;Q3] 19 [13-43] 20 [11-48] 0.719  
Duration of response     
Months with eltrombopag, median [Q1;Q3] 9 [6-19] 12 [4-18] 0.909  
Platelet response (R) at 3 months, n (%) 46 (65.7) 51 (68.0) 0.770  
Platelet complete response (CR) at 3 months, n (%) 35 (50.0) 37 (49.3) 0.936  
Platelet response (R) at 6 months, n (%) 41 (58.5) 42 (56.0) 0.754  
Platelet complete response (CR) at 6 months, n (%) 34 (48.5) 32 (42.7) 0.476  
Days on response, median [Q1;Q3] 274 [175;517] 340 [126;529] 0.870  
Days on platelet complete response (CR), median [Q1;Q3] 202 [113;366] 267 [79;416] 0.715  
Treatment failure or relapse     




























Number of patients with treatment failure or relapse 18 (25.7) 18 (24.0) 0.668  
Treatments after eltrombopag     
Immunoglobulins 3 (4.3) 13 (17.3) 0.315  
Steroids 0 (0) 4 (5.3) 0.211  
Romiplostim 1 (1.4) 0 (0) 0.231  
Rituximab 1 (1.4) 2 (2.7) 1.000  
Azathiprine 0 (0) 1 (1.3) 0.311  
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Table 6. Adverse events during eltrombopag treatment: 65-74 yr-old and ≥75 yr-old ITP cohorts 
                                  
Table 6.  Adverse events during eltrombopag treatment 65-74 yr-old ITP ≥75 yr-old ITP 
Variable n (%) n (%) 
Any adverse event 30 (42.8) 33 (44.0) 
Number of grade 3-4 events† 10 (14.3) 14 (18.7) 
Brain hemorrhage  2 4 
Gastrointestinal bleeding 0 1 
Upper respiratory tract infection 1 4 
Rash 1 0 
Cataract 0 1 
Urinary tract infection 0 1 
Transient  ischemic attack (TIA) 0 1 
Hepatobiliary laboratory abnormalities  (HBLA) 8 1 
Diarrhea 2 4 
Headaches 4 3 
Sepsis  3 3 
Asthenia 1 2 
Arthralgia 4 0 
Myalgia 2 0 
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 Abdominal pain 1 1 
Neoplasms 1 1 
Venous thromboembolism 0 2 
Increase of reticulin in bone marrow 0 1 
Cardiac insufficiency 0 1 
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Table 7. Deaths of whole elderly ITP cohort 
        
 Table 7.  Deaths during eltrombopag treatment ITP type ITP subtype Platelet count Age Underlying disease 
Cause of death      
Pneumonia Primary ITP Newly diagnosed ITP 104 84 Chronic obstructive pulmonary disease 
Brain hemorrhage Primary ITP Newly diagnosed ITP 7 79 - 
Brain hemorrhage Primary ITP Chronic ITP 1 73 - 
Brain hemorrhage Primary ITP Chronic ITP 12 84 - 
Gastrointestinal bleeding Primary ITP Chronic ITP 42 77 - 
Sepsis of respiratory origin Primary ITP Chronic ITP 140 78 - 
Sepsis of respiratory origin Primary ITP Chronic ITP 107 66 - 
Splenectomy septic complications Primary ITP Chronic ITP 211 68 - 
Brain hemorrhage Secondary ITP Immune disorders 4 80 Evans syndrome 
Acute myeloid leukemia Secondary ITP Immune disorders 75 71                              SLE 
JAK2+ Myelofibrosis Secondary ITP Immune disorders 22 78 HCV 
Febrile neutropenia Secondary ITP Neoplastic condition 24 83 CLL 
Sepsis of unknown origin Secondary ITP Neoplastic condition 84 74 Waldenstrom macroglobulinemia 
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